NDC product
Efavirenz
NDC 33342-013 · Macleods Pharmaceuticals Limited
Key facts
| Product NDC | 33342-013 |
|---|---|
| Proprietary name | Efavirenz |
| Nonproprietary name | Efavirenz |
| Substances | EFAVIRENZ |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Macleods Pharmaceuticals Limited |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA091579 |
| Pharmacologic classes | Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] and 2 more |
| Marketing start | May 10, 2024 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: